The Kenyan government has reassured HIV/AIDS patients of a steady supply of antiretroviral drugs (ARVs) following the recent decision by the United States to reduce foreign aid. Speaking to reporters in Naivasha on Wednesday, Medical Services Principal Secretary Harry Kimtai emphasized the Ministry’s commitment to reallocating resources to essential health programs as a sustainability strategy.
Kimtai stated that the government has sufficient ARV stocks to support over 1.4 million individuals living with HIV/AIDS. “Patients need not be concerned, as we will collaborate with the Treasury to ensure ongoing funding for ARVs, malaria treatment, and tuberculosis care. We are looking into additional funding avenues through the Treasury,” he affirmed.
Additionally, Kimtai announced plans to introduce a Quality of Care Bill aimed at enhancing healthcare standards across both public and private facilities. This proposed legislation seeks to improve access to quality healthcare and elevate service delivery within the sector.
Esther Ngari, Managing Director of the Kenya Bureau of Standards (KEBS), highlighted the launch of a new healthcare management system designed to streamline operations in health facilities nationwide. This initiative aims to boost efficiency and transform the overall healthcare landscape.
This development follows the suspension of programs by the United States Agency for International Development (USAID), the Centers for Disease Control and Prevention (CDC), and the President’s Emergency Plan for AIDS Relief (PEPFAR) in response to a funding cut mandated by former President Trump. The PEPFAR initiative has been instrumental in providing critical medications to HIV/AIDS patients, helping to reduce infection rates and improve access to treatment.
The implications of this funding cut are likely to resonate across several African nations that rely on USAID support. In light of these changes, African leaders are actively seeking alternative funding solutions to sustain vital health programs.
